#United States #ClorDiSys #Chlorine Dioxide #Branchburg #Cold-Chain Sterilization

New Study on Chlorine Dioxide Gas for Product Sterilization

In a significant breakthrough in sterilization technology, Clordisys has unveiled a peer-reviewed study published in PLOS ONE that showcases the efficiency of chlorine dioxide (ClO₂) gas for sterilizing cold-chain products. This method is emerging as a preferable alternative to traditional sterilization techniques, especially for pharmaceuticals and medical devices that require careful temperature management.

The Challenge of Sterilizing Cold-Chain Products

Cold-chain products, such as prefilled syringes, pose unique sterilization challenges due to their sensitivity to heat. Conventional sterilization methods, especially ethylene oxide (EO), can compromise the integrity of these products. EO relies on elevated temperatures and extended processing times, often leading to increased exposure of the products to conditions that could diminish their effectiveness or safety. Furthermore, EO can leave harmful residues that necessitate off-gassing procedures to reduce toxicity – a particular concern for combination products containing drugs, which risk contamination with residual EO.

The newly published study titled Chlorine Dioxide Gas Sterilization of Cold-Chain or Temperature-Sensitive Devices provides a thorough examination of how chlorine dioxide gas can sterilize products without the need for high temperatures. Unlike conventional methods, the chlorine dioxide process was conducted at ambient temperatures, keeping the products below 21°C. This approach not only preserves the drug's integrity but also reduces the sterilization cycle time significantly, averaging just three hours and 45 minutes.

Key Findings of the Study

One of the compelling findings from the study is that chlorine dioxide gas sterilization did not show any ingress into the syringe content during testing, which addresses one of the major concerns with sterilization processes. This confirmed that the method is capable of keeping both medical devices and pharmaceuticals sterile without compromising their safety.

Furthermore, the efficiently validated chlorine dioxide cycle proved to be ten times quicker than the corresponding EO sterilization cycle for similar products, significantly optimizing the supply chain processes. This method also better aligns with the rigorous requirements for maintaining temperature-sensitive products throughout their lifecycle, from manufacturing to delivery.

Implications for the Medical Field

The results of this research highlight chlorine dioxide as an effective terminal sterilization alternative for manufacturers of pharmaceuticals and medical devices. By opting for this method, companies can potentially enhance product safety while minimizing the risks associated with EO sterilization. As the healthcare industry increasingly seeks solutions that meet growing regulatory requirements and safety standards, adopting chlorine dioxide technology can help streamline processes while safeguarding product integrity.

Established in 2001, Clordisys has developed its chlorine dioxide technology in collaboration with industry leaders like Johnson & Johnson, and it has been a trusted name in sterilization for over 25 years. The company’s findings could pave the way for broader adoption of this safer sterilization method in the medical and pharmaceutical sectors, where maintaining the efficacy and safety of temperature-sensitive products is a top priority.

Conclusion

Through innovative research, Clordisys is leading the conversation on how the sterilization of cold-chain products can evolve. With the advantages presented by chlorine dioxide gas sterilization, there lies an exciting potential for improved practices that prioritize patient safety and product reliability in the healthcare landscape. As pharmaceutical companies and medical device manufacturers adopt these findings, the transition to safer sterilization could reshape standards and practices across the industry.